Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 22, Issue 24, Pages -Publisher
MDPI
DOI: 10.3390/ijms222413317
Keywords
latent tuberculosis infection; dormant Mycobacterium tuberculosis; LTBI treatment; anti-TB drugs
Funding
- Russian Science Foundation [21-15-00042, rscf.ru/project/21-15-00042]
- Russian Science Foundation [21-15-00042] Funding Source: Russian Science Foundation
Ask authors/readers for more resources
Current guidelines for managing latent tuberculosis infection (LTBI) only include three older drugs, which have little impact on eliminating latent TB. New specific therapeutics are urgently needed to address this challenge.
Latent tuberculosis infection (LTBI) represents a major challenge to curing TB disease. Current guidelines for LTBI management include only three older drugs and their combinations-isoniazid and rifamycins (rifampicin and rifapentine). These available control strategies have little impact on latent TB elimination, and new specific therapeutics are urgently needed. In the present mini-review, we highlight some of the alternatives that may potentially be included in LTBI treatment recommendations and a list of early-stage prospective small molecules that act on drug targets specific for Mycobacterium tuberculosis latency.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available